department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

ITB-Med AB · pharmadog

PUBLIC COMPANY

ITB-Med AB

updated 1mo ago

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 2

Transplant Rejection

T-cell surface antigen CD2

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view ITB-Med AB jobs →

News

no news has mentioned this company yet

identifiers

source

globaldata

top tags

mentioned in

0news items

entity-linker matched

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase1A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patientsrecruitingn=48
phase2A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantationterminatedn=33
phase2A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)active not recruitingn=18
phase2A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)terminatedn=4
phase2A Study of TCD601 in de Novo Renal Transplant Recipientsactive not recruitingn=76
phase2A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patientsterminatedn=9
phase2A Dose Escalation Study in de Novo Renal Transplantationcompletedn=13
phase2A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantationactive not recruitingn=12

more trials →